Business briefs: Sobi and Savient; Novartis; Saatchi & Saatchi Wellness

Share this article:

Sobi and Savient Pharmaceuticals inked a co-promote agreement for RA drug Kineret in the US. Savient's sales organization details US rheumatologists for gout drug Krystexxa. “The collaboration will expand our reach to US physicians who treat patients suffering from rheumatoid arthritis and augment our own ability to directly support the pediatric community,” said Sobi chief operating officer Alan Raffensperger. The agreement grants Savient exclusive rights to co-promote the drug with Sobi in the US starting in April. Sobi retains responsibility for manufacturing, supply, safety and regulatory activities. 

FDA approved Novartis' Zortress for prevention of organ rejection in adult liver transplant patients. The mTOR inhibitor is already approved for kidney transplants in the US, and was approved by European health authorities for adult liver transplants under the brand name Certican in Q4. It's the first new drug in over a decade approved by FDA for prevention of organ rejection in adult liver transplant patients.

Saatchi & Saatchi Wellness named Kathy Delaney chief creative officer. Delaney, who also becomes global chief creative officer of the Saatchi & Saatchi Health network, joins from her own consultancy, which launched the SK Energy Shots brand in partnership with Pure Growth Partners. From 2007 to 2011, she served as chief creative officer and president of digital botique Nitro until its sale to Sapient. She succeeds Helayne Spivak, who left Saatchi & Saatchi Wellness in August to Virginia Commonwealth University's VCU Brandcenter.

Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.